TRINETRA › Sectors › Healthcare
Aurobindo Pharma Limited (AUROPHARMA) — share price, P/E and fundamentals
Aurobindo Pharma Limited (NSE: AUROPHARMA) closed at ₹1,681.40 on 30 Oct 2026, +52.7% over one year, against a 52-week range of ₹1,080.10 – ₹1,740.00.
In the quarter ended 30 Jun 2026 (consolidated, filed 5 Aug 2026) it reported revenue of ₹9,150 cr and net profit of ₹1,033 cr, a 11.3% net margin; revenue grew 16.3% and profit grew 25.9% year on year.
On four consecutive filed quarters its trailing P/E is 26.1; since 27 May 2025 its own P/E has ranged from 17.1 to 27.1 (median 20.3), and today's reading is higher than 93% of those 353 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 10.9%, ROCE 16.0%, debt-to-equity 0.20, Piotroski F-score 6 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 30% of 63 sector peers; PBT margin higher than 46% of 63 sector peers; ROE higher than 30% of 63 sector peers.
Key figures
| Last close | ₹1,681.40 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -2.0% / +18.9% / +52.7% |
| 52-week low – high | ₹1,080.10 – ₹1,740.00 |
| Market capitalisation | ₹96,748 cr |
| Trailing P/E | 26.1 |
| Price / book | 2.55 |
| EV / EBITDA | 12.7 |
| Earnings yield | 3.8% |
| TTM EPS | ₹64.52 |
| TTM net profit | ₹3,713 cr |
| Quarter revenue | ₹9,150 cr |
| Quarter net profit | ₹1,033 cr |
| Net margin | 11.3% |
| Revenue growth (YoY) | +16.3% |
| Profit growth (YoY) | +25.9% |
| Return on equity | 10.9% |
| ROCE | 16.0% |
| Debt / equity | 0.20 |
| Current ratio | 1.81 |
| Free cash flow | ₹2,841 cr |
| Piotroski F-score | 6 / 9 |
| Average daily turnover (50 days) | ₹131.4 cr |
Against Healthcare peers
| Metric | AUROPHARMA | Peer median | Percentile |
|---|---|---|---|
| Net margin | 11.28 | 12.89 | 30 |
| PBT margin | 16.57 | 17.68 | 46 |
| ROE | 10.90 | 13.87 | 30 |
| ROCE | 16.00 | 17.26 | 44 |
| Debt / equity | 0.20 | 0.11 | 62 |
| Cash conversion | 1.58 | 1.25 | 77 |
| Trailing P/E | 26.06 | 43.26 | 15 |
| P/B | 2.55 | 6.02 | 7 |
Questions
What is the P/E ratio of Aurobindo Pharma Limited?
Aurobindo Pharma Limited's trailing P/E is 26.1, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 27 May 2025 its P/E has ranged 17.1–27.1.
What were Aurobindo Pharma Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Aurobindo Pharma Limited reported revenue of ₹9,150 cr and net profit of ₹1,033 cr (consolidated), filed with the exchange on 5 Aug 2026.
What is Aurobindo Pharma Limited's ROE?
Return on equity is 10.9% based on the balance sheet dated 31 Mar 2026.
Does Aurobindo Pharma Limited have debt?
Debt-to-equity is 0.20 on the balance sheet dated 31 Mar 2026.
What is AUROPHARMA's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, AUROPHARMA traded between ₹1,080.10 and ₹1,740.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
- Glenmark Pharmaceuticals Limited (GLENMARK)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.